Pelthos Therapeutics Inc.
PTHS
AMEX·Healthcare·Biotechnology·Mkt cap $84.6M
$24.35
▼ -0.04%
P/E
-2.51
Mkt Cap
$84.6M
52-Wk Range
$18.19–$37.50
52-Week Range
$18.19 - $37.50
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 24.3% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
No bull reasons captured for this rating yet.
Bear Case
1 risk
- Very high volatility (beta 3.0). Expect 3x market swings. Position size accordingly.
Growth
Strong growth ahead
Value
Deep value opportunity - significant discount to sector peers
Momentum
Weak
-7.4% over 3m
Quality
Strong
Below average quality
Dividend
None
No dividend
Smart-money signal
Who's buying PTHS right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 12, 2026
AUG 13, 2026
Reported EPS of -$6.62 vs -$2.82 consensus (-134.8% surprise). Revenue of $15.6M vs $15.2M expected (+2.8%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-134.8%
Revenue trend · last 2Q
—
—
Q1 26
Q2 26
$10.9M
$15.6M
Margins · last 2Q
Gross
68.4%
Operating
-111.0%
Profit
-150.1%
Wall Street consensus
2 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Oppenheimer · Aug 14, 2026
vs Industry
How PTHS stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.